# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:ANGO) with a Buy and maintains $14 price target.
The CE Mark for the AlphaVac F1885 System expands treatment options for healthcare professionals in the EU by offering a tool t...
New data finds AlphaVac F1885 System safe in patients with acute intermediate-risk pulmonary embolism (PE) and provides signifi...
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades.
Oppenheimer analyst Steven Lichtman upgrades AngioDynamics (NASDAQ:ANGO) from Perform to Outperform and announces $12 price ...
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens tr...
AngioDynamics (NASDAQ:ANGO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.1...